Evaluating RGO's Therapeutic Effects on LPS-Induced Intestinal Inflammation in Mice

We purchased 36 KM mice from Henan Scribes Biotechnology Co., Ltd. The mice were fed for 7 days before the experiment to acclimate to the environment. The mice were randomly divided into six groups, namely normal (N), model (M), treatment (T), RGO low dose (RL, 0.25 g/kg), RGO medium dose (RM, 0.5 g/kg), and RGO high dose (RH, 1 g/kg) groups. Six mice were in each group, and the test period was 21 days. Except for the normal group, on the 9th, 13th, 17th, and 21st days, 0.2 mL of normal saline was injected intraperitoneally. 0.2 mL of 1 mg/kg LPS was injected intraperitoneally in all other groups to develop mice models of intestinal inflammation and barrier injury (14 (link), 15 (link)). From the first day of the test, mice in RL, RM, and RH groups were provided 0.2 mL of RGO solution by gavage once a day for 21 days. The mice in the N, M, and T groups were gavaged with an equal volume of normal saline daily. After each intraperitoneal LPS injection, the mice in the T group were gavaged with 0.2 mL dexamethasone solution at 0.5 mg/kg dose 30 min. All the groups were fed adequate food and free to drink water. The weight of mice was determined on the 1^st, 7^th, 14^th, and 21^st days of the test. Additionally, the food intake, fecal properties, and health status of mice were observed and recorded daily.